CARL BYERS

Carl Byers serves as a distinguished Partner at F-Prime Capital Partners, a global venture capital firm renowned for its strategic investments in groundbreaking companies. Based in Cambridge, Massachusetts, Mr. Byers is a pivotal member of the firm's healthcare investment team, bringing extensive operational and investment expertise to the table. His primary focus lies within the dynamic and rapidly evolving healthcare sector, where he actively seeks out and champions innovative companies poised to transform patient care.

Mr. Byers' investment strategy at F-Prime Capital Partners is deeply rooted in identifying opportunities across several key healthcare verticals. He specializes in biotechnology, medical devices, digital health, and diagnostics, demonstrating a keen eye for disruptive technologies and solutions that address significant unmet medical needs. His portfolio reflects a commitment to supporting companies developing novel therapeutics, advanced medical technologies, and digital platforms designed to improve healthcare delivery and outcomes. He is known for his hands-on approach, often taking active board roles to guide portfolio companies through critical growth stages, from early stage development to market leadership.

Before joining F-Prime Capital Partners in 2012, Carl Byers built a robust career marked by both entrepreneurial success and strategic investment leadership. He notably co-founded and served as the Chief Operating Officer and Chief Financial Officer of Generation Health, a pioneering company focused on personalized medicine and pharmacogenomics, which was successfully acquired by CVS Caremark. This experience provided him with invaluable insights into building and scaling healthcare enterprises. Prior to Generation Health, Mr. Byers was a Principal at Polaris Venture Partners, where he honed his skills in healthcare venture capital, identifying and nurturing promising early stage companies. His foundational career experience also includes a tenure at McKinsey & Company, a global management consulting firm, where he advised clients across various industries.

Carl Byers' academic background further underpins his strategic acumen. He earned his Master of Business Administration from Harvard Business School and holds a Bachelor of Arts from Dartmouth College. This blend of academic rigor and practical experience equips him with a comprehensive understanding of both the scientific and business aspects of the healthcare industry.

Throughout his career, Mr. Byers has been instrumental in the growth and success of numerous companies. His notable investments and board affiliations include Akouos (acquired by Eli Lilly), a genetic medicine company; Orchard Therapeutics, a commercial stage gene therapy company; Spero Therapeutics, focused on novel antibiotics; Denali Therapeutics, a biopharmaceutical company addressing neurodegenerative diseases; Rhythm Pharmaceuticals, developing therapies for rare genetic disorders of obesity; and Valo Health, a technology company transforming drug discovery and development. His contributions have consistently helped these companies achieve significant milestones, bringing innovative treatments and technologies closer to patients worldwide. Carl Byers continues to be a driving force in healthcare innovation, leveraging his expertise to shape the future of medicine through strategic venture capital.